Calidi Biotherapeutics Received Notice of Noncompliance

On September 21, 2026, the company received a notice from NYSE American that it is not in compliance with Section 1003(a)(ii) due to stockholders' equity of $3.1 million versus the $4.0 million requirement and losses in three of its last four fiscal years. The company has until October 21, 2026 to…